RT Journal Article
SR Electronic
T1 Profiling of circulating chromosome 21-encoded microRNAs, miR-155 and Let-7c, in Down Syndrome People
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.24.20218677
DO 10.1101/2020.10.24.20218677
A1 Pérez-Villareal, Jesús Manuel
A1 Aviña-Padilla, Katia
A1 López, Evangelina Beltrán
A1 Guadrón-Llanos, Alma Marlene
A1 López-Bayghen, Esther
A1 Magaña-Gómez, Javier
A1 Meraz-Ríos, Marco Antonio
A1 Varela-Echavarría, Alfredo
A1 Angulo-Rojo, Carla
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.24.20218677.abstract
AB Down syndrome (DS), or Trisomy 21 (Ts21), is the most common chromosomal survival aneuploidy. Nevertheless, people with DS have compromised health, and the increase in their life expectancy further heightens the risk of developing chronic degenerative diseases such as obesity, dyslipidemias and diabetes mellitus associated with higher morbidity, and mortality for cardiovascular disease from an early age. DS is also accompanied by a higher risk of neurodegeneration. The extra genetic material that characterizes DS causes an imbalance in the genetic dosage, including overexpression of miR-155 and Let-7c miRNAs, both associated with cognitive impairment and dementia in adults. The dynamics of expression of their putative target genes in the early stages of the development of DS and their clinical associations, however, remain to be ascertained. This study aimed to evaluate the relative expression of miR-155 and Let-7c in young and adult individuals with DS and its possible association with biochemical indicators of lipid metabolism. The anthropometric, clinical, biochemical, and gene expression features of miR-155 and Let-7c were analyzed in a population of 52 control and 50 DS subjects divided into groups of 20 years of age or younger and 21 years or older. Expression changes for miR-155 were not significant. Nevertheless, a negative correlation for HDL-Cholesterol concentrations and miR-155 expression was identified. Notably, Let-7c was overexpressed in DS from young and old ages. Overall, our results suggest that Let-7c is related from early stages to cognitive impairment in DS, while a similar role of miR-155 in late stages could be mediated by alterations in lipid metabolism. Further studies with both miRNAs will shed light on their potential as therapeutic targets to prevent or delay cognitive impairment in DS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCAR obtained financial support for this project from Universidad Autonoma de Sinaloa (PROFAPI2014/015 and PROFAPI2015/015) (https://www.uas.edu.mx/). KAP received a Postdoctoral fellowship from Universidad Autonoma Nacional de Mexico (DGAPAUNAM) (https://www.unam.mx/) and JMPV received a Master fellowship from Consejo Nacional de Ciencia y Tecnologia (CONACyT) (https://www.conacyt.gob.mx/). We declare that sponsors did not play any role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study followed the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines, and the local institutional review board approved the protocol. The research project was reviewed and approved by the Research Ethics Committee at the Medicine Faculty of Autonomous University of Sinaloa, which has a national certification (CONBIOETICA-25-CEI-003-20181012) for its duties. Parents or legal guardians of people with DS were informed before the evaluation and provided written consent to undergo study procedures.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe declare that all data referred to in the manuscript is available and subject to any revision.